Skip to main content

Advertisement

Table 1 Regional target product profiles

From: Report of the Post Kala-Azar Dermal Leishmaniasis (PKDL) consortium meeting, New Delhi, India, 27–29 June 2012

Target profile South Asia Africa
Risk:Benefit Must be very high Parasitological cure must be achieved No direct associated mortality with symptomatic treatment
Ease of use   Feasible to use at the level of a health clinic
Course of treatment Very short course of treatment to facilitate compliance Minimum acceptable treatment for children: one week (similar to antibiotics)
Cold chain requirements Ideally not cold chain dependent  
Cost factors Cost is less important than commitment to treatment  
Concomitant infections   With HIV co-infection, no antimonials or monotherapies